Back To Top

Advancing science and medicine through great software.

Learn more

What we do

We are a London-based health-tech company, developing game-changing software for bioinformatics and healthcare to drive and innovate medical research world-wide, from UK to Japan. We have a scientific and medical background and specialise in genetics, methylation and image analysis.

Our flag-ship products include Phenopolis and Octavius, with several others in the pipeline including, Phenogenon, EpiClockR and Docsnap.

If you have an interesting product which you like us to develop bespoke for you as industrial partners or academic collaborators, please free to get in touch.

Scientifically Sound Software &
Web Applications.

Experts in Cloud &
On Premises Analysis Pipeline.

Experts in processing
Big Data efficiently.

Fully Encrypted (AES256)
patient-identifiable data.

Stylish & Streamlined
User Interfaces.

On-going Support Available.

Our Work

Here are a few of the products that we have worked on.


An online platform for Genetic & Phenotype Data

A website providing an intuitive interface to genetic and phenotypic databases. It provides variant filtering and gene prioritization based on the Human Phenotype Ontology. The Phenopolis platform accelerates clinical diagnosis, gene discovery and encourages adoption of the Human Phenotype Ontology in the study of rare genetic diseases.


Leading imaging platform for storing, viewing OCT images online

An imaging platform allowing healthcare professionals in ophthalmology to easily upload, share their imaging data and present their cases interactively in a conference setting for educational purposes. We support all major optical coherence tomography vendor supported.


An interactive online platform for predicting phenotypes using methylation data.

An interactive online platform that implements a comprehensive and systematic pipeline of all major epigenetic clocks and other predictors, such as smoking status. Users may upload their own data and instantly compare different results produced from multiple epigenetic predictors.


A metric for identifying novel genotype to phenotype associations

An analysis and visualisation tool that combines, Human Phenotype Ontology defined patient phenotypes, population allele frequency, and variant pathogenicity prediction, in order to uncover gene to phenotype associations.


A secure photography app for Healthcare professionals

Users can tag images and add comments, allowing them to discuss cases with colleagues in a secure environment. Anonymised images with the required level of consent can be exported into presentations and publications, and can also be printed using AirPlay enabled devices.

Meet the Team

Phenopolis is run by an experienced team of forward-thinking bioinformaticians, scientists, engineers and entrepreneurs.

Dr Nikolas Pontikos

Co-Founder and CEO

Nikolas co-founded Phenopolis in August 2018 with Ismail to build great software to service science and medicine. He has over 12 years experience in science and software development. He has published over 50 papers in the last five years. He is also a Principal Investigator at UCL.

Ismail Moghul

Co-Founder and CTO

Ismail co-founded Phenopolis with Nikolas. He is a serial entrepreneur with a lot of experience in the health tech sector. He specialises in cloud computing and building web services for scientific projects. He is currently completing his PhD at UCL where he is using Deep Learning to answer some of the big questions in the field of Methylation.

Dr Jing Yu

Pipeline Engineer

Jing helped kickstart Phenopolis. He specialises in building whole exome and genome sequencing analysis pipelines and data visualisation. He has extensive experience in pathogen and human genetics research.

Dr Yuan Tian

Front-end Developer

Tian has over 5 years experience in bioinformatics and software development. He specialises in epigenetics and cross-omics. He is skilled in JavaScript and R.

Contact Us

Want to say hello? Want to know more about us? Give us a call or drop us an email and we will get back to you as soon as we can.